We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: basal insulin
MedXY News
EnglishTag

basal insulin

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances
Clinical Updatessemaglutidehypoglycaemia

Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances

By MedXY|Aug 15, 2026

COMBINE 4 demonstrated that once-weekly IcoSema (icodec+semaglutide) offers superior glycemic control, weight reduction, and reduced hypoglycemia versus daily insulin glargine U100 in insulin-naive type 2 diabetes patients, supported by com

Efficacy and Safety of Tirzepatide Added to Basal Insulin in Chinese Patients with Type 2 Diabetes: Insights from the SURPASS-CN-INS Phase 3 Trial
Diabetes & Endocrinologybasal insulinChina

Efficacy and Safety of Tirzepatide Added to Basal Insulin in Chinese Patients with Type 2 Diabetes: Insights from the SURPASS-CN-INS Phase 3 Trial

By MedXY|Nov 17, 2025

This phase 3 study demonstrates that adding tirzepatide to basal insulin significantly improves glycemic control in Chinese patients with type 2 diabetes, with a manageable safety profile.

Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes
Clinical Updatesbasal insulinclinical trial

Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes

By MedXY|Oct 2, 2025

Weekly fixed-dose insulin efsitora demonstrated noninferiority to daily glargine in reducing HbA1c in insulin-naïve type 2 diabetes, with fewer hypoglycemic events and simpler dose adjustment.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story